Risk of New, Undisclosed SEC Probe Adds to Valeant Pharmaceuticals’ Woes


Disclosure Insight™ reports provide commentary and analysis on public company interactions with investors and with the SEC.  They are heavily reliant on our expertise with using the Freedom of Information Act. 

Editor’s noteThis report warning of risk of an undisclosed SEC probe at Valeant, as well as our opinion of the raised potential for a restatement and delayed filings, was already loaded and set for release at the time the Wall Street Journal broke news last evening of a pending restatement.  We decided to keep our original report intact, but wanted to acknowledge our awareness of the Journal’s story.  We remain first on breaking news of data pointing to an undisclosed SEC probe.

Valeant Pharmaceuticals International, Inc.  $VRX 

  • Possible Undisclosed SEC Investigation of Valeant.
  • Salix investigations remain an on-going exposure.
  • Restatement and delayed filings risk elevated.
  • Added to Watch List

Analyst Summary:  With new SEC data pointing to a new and undisclosed SEC investigation of Valeant, and the company’s own filings indicating a previously-disclosed, formal SEC investigation of Salix is on-going, the risk for delayed filings and restatements is elevated.  

To access the full report, simply click on the PDF posted here.  Documents, when available, are also accessible by clicking on the links.

To learn more about our research process, including how to best use this information in your own decision-making, click here.

Our Terms of Service, trading policy, relevant disclosures, and other legal notices can be found here.  

Copyright Warning and Notice

The works of authorship contained in the accompanying material, including but not limited to all data, design, text, images, charts and other data compilations or collective works are owned by Probes Reporter, LLC or one of its affiliates and may not be copied, reproduced, transmitted, displayed, performed, distributed, rented, sublicensed, altered, or stored for subsequent use, in whole or in part in any manner, without the prior written consent of Probes Reporter, LLC.

Photocopying or electronic distribution of any of the accompanying material or contents without the prior written consent of Probes Reporter, LLC violates U.S. copyright law, and may be punishable by statutory damages of up to $150,000 per infringement, plus attorneys’ fees (17 USC 504 et. seq.). Without advance permission, illegal copying includes regular photocopying, faxing, excerpting, forwarding electronically, and sharing of online access.


Probes Reporter, LLC is not an investment adviser and does not offer or provide personalized investment advice. The information in our reports and appearing on ProbesReporter.com is not a solicitation connected to any security. The information we provide is obtained from company submissions and our own Freedom of Information requests made to the Securities and Exchange Commission. No representation or warranty is made as to the timeliness or completeness of any information found in our reports or on ProbesReporter.com.

Probes Reporter does not adopt the truth or falsity of the contents of any of the documents or filings referred to on this website, and no conclusion of wrongdoing should be inferred from the fact that an investigation has been initiated by the SEC. Probes Reporter is not the guarantor of any investment and cannot be held liable for any losses or expenses incurred as a result of reliance upon any information contained herein, and ProbesReporter.com is not a substitute for your own due diligence, which may include advice from an investment professional.

With few exceptions, Probes Reporter, LLC prohibits its employees and principals from trading of any kind in any individual public company securities, or derivatives thereof, on any company on which production of any new research report has commenced.  Such prohibitions shall remain in place until either 5 days after the individual research report has been published or its production otherwise ceases.   

Probes Reporter, LLC does not engage in investment banking activities or take any security positions, except those necessary for routine corporate treasury functions

Our full trading policy, along with our Terms of Service, relevant disclosures, and other legal notices can be found here.  

Intellectual Property

© 2016 Probes Reporter, LLC. All rights reserved.  Probes Reporter®; They Know it.  Now You Know It.®; Better Disclosure for Better Decisions™; Disclosure Insight™;  and, Disclosure Games™, are trademarks of Probes Reporter, LLC and are proprietary.